October 19, 2017 / 6:47 AM / 9 months ago

BRIEF-Novo Nordisk VP says seeks market share from Eli Lilly with semaglutide

Oct 19 (Reuters) - NOVO NORDISK CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN SAYS IN INTERVIEW:

* SEMAGLUTIDE WILL TAKE MARKET SHARE FROM ELI LILLY’S TRULICITY IN GLP-1 SEGMENT

* SEMAGLUTIDE WILL BE PRICED IN RANGE WITH EXISTING GLP-1 DRUGS, MAYBE WITH SMALL PREMIUM

* WILL SEEK TO EXPAND U.S. MARKET FOR GLP-1 DRUGS WITH SEMAGLUTIDE Further company coverage: (Reporting by Jacob Gronholt-Pedersen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below